Sigal Pressman
Overview
Explore the profile of Sigal Pressman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
372
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carasso S, Zaatry R, Hajjo H, Kadosh-Kariti D, Ben-Assa N, Naddaf R, et al.
Cell Host Microbe
. 2024 Feb;
32(3):322-334.e9.
PMID: 38423015
Reversible genomic DNA inversions control the expression of numerous gut bacterial molecules, but how this impacts disease remains uncertain. By analyzing metagenomic samples from inflammatory bowel disease (IBD) cohorts, we...
2.
Gerassy-Vainberg S, Starosvetsky E, Gaujoux R, Blatt A, Maimon N, Gorelik Y, et al.
Cell Rep Med
. 2023 Dec;
5(1):101300.
PMID: 38118442
Personalized treatment of complex diseases has been mostly predicated on biomarker identification of one drug-disease combination at a time. Here, we use a computational approach termed Disruption Networks to generate...
3.
Bar-Yoseph H, Blatt A, Gerassy S, Pressman S, Mousa A, Sabo E, et al.
J Crohns Colitis
. 2021 Dec;
16(6):884-892.
PMID: 34849649
Background And Aims: Therapeutic drug monitoring is used to guide anti-tumour necrosis factor [TNF] therapy. However, the associations between serum drug levels [SDL], TNF-bound, and free anti-TNF in the target...
4.
Gorelik Y, Freilich S, Gerassy-Vainberg S, Pressman S, Friss C, Blatt A, et al.
Gut
. 2021 Aug;
71(2):287-295.
PMID: 34344783
Objective: Anti-drug antibodies (ADA) to anti-tumour necrosis factor (anti-TNF) therapy drive treatment loss of response. An association between intestinal microbial composition and response to anti-TNF therapy was noted. We therefore...
5.
Bar-Yoseph H, Pressman S, Blatt A, Gerassy Vainberg S, Maimon N, Starosvetsky E, et al.
Gastroenterology
. 2019 Aug;
157(5):1338-1351.e8.
PMID: 31401142
Background & Aims: Some patients develop anti-drug antibodies (ADAs), which reduce the efficacy of infliximab, a monoclonal antibody against tumor necrosis factor (TNF), in the treatment of immune-mediated diseases, including...
6.
Gaujoux R, Starosvetsky E, Maimon N, Vallania F, Bar-Yoseph H, Pressman S, et al.
Gut
. 2018 Apr;
68(4):604-614.
PMID: 29618496
Objective: Although anti-tumour necrosis factor alpha (anti-TNFα) therapies represent a major breakthrough in IBD therapy, their cost-benefit ratio is hampered by an overall 30% non-response rate, adverse side effects and...
7.
Church V, Pressman S, Isaji M, Truscott M, Terzi Cizmecioglu N, Buratowski S, et al.
Cell Rep
. 2017 Sep;
20(13):3123-3134.
PMID: 28954229
The cellular abundance of mature microRNAs (miRNAs) is dictated by the efficiency of nuclear processing of primary miRNA transcripts (pri-miRNAs) into pre-miRNA intermediates. The Microprocessor complex of Drosha and DGCR8...
8.
Weisshof R, Ungar B, Blatt A, Dahan A, Pressman S, Waterman M, et al.
Inflamm Bowel Dis
. 2016 Apr;
22(7):1655-61.
PMID: 27120567
Background: About 60% of infliximab (IFX)-treated patients develop antidrug antibodies (ADA), although their clinical significance remains disputed. The aim of this study was to develop an assay for assessing ADA-neutralizing...
9.
Pressman S, Reinke C, Wang X, Carthew R
G3 (Bethesda)
. 2012 Apr;
2(4):437-48.
PMID: 22540035
A central goal of microRNA biology is to elucidate the genetic program of miRNA function and regulation. However, relatively few of the effectors that execute miRNA repression have been identified....
10.
Lee Y, Pressman S, Andress A, Kim K, White J, Cassidy J, et al.
Nat Cell Biol
. 2009 Aug;
11(9):1150-6.
PMID: 19684574
Small RNAs direct RNA-induced silencing complexes (RISCs) to regulate stability and translation of mRNAs. RISCs associated with target mRNAs often accumulate in discrete cytoplasmic foci known as GW-bodies. However, RISC...